Peptide stacking for women over 30: what the evidence shows

What did @jenskin1181 actually say?

She walked through her personal peptide layering process, starting with a GLP-1 medication, then adding CJC-1295 with ipamorelin for body composition, GHK-Cu for skin, NAD for energy, and Semax for cognitive focus. Her core advice: add one thing at a time so you can actually tell what's working.

This is a first-person experience video, not a medical recommendation, but it functions as one for the 6,900 people who watched it. She frames each peptide as doing a specific job, which sets up real expectations in real people. The "start one at a time" advice is actually the most defensible thing she says. The specific benefit claims deserve more scrutiny.

Does the science back this up?

Partially, with significant gaps. The CJC-1295 and ipamorelin combination has some research support for growth hormone secretion, but the body composition benefits in healthy adults are weaker than the peptide community suggests.

CJC-1295 (a GHRH analog) has been studied in small trials. Ionescu and Frohman (2006, Growth Hormone and IGF Research) confirmed it raises GH and IGF-1 levels. Whether that translates to meaningful body composition changes in non-deficient adults is a separate question, and the evidence there is thin. Ipamorelin's human data is limited mostly to post-surgical contexts. GHK-Cu has interesting in vitro and animal data on skin collagen, but controlled human trials are sparse. Pickart and Margolina (2018, Symmetry) reviewed its biological activity but acknowledged the clinical evidence base is immature. NAD precursors have more robust human data, though the creator is likely using injectable NAD, which has a different absorption profile than studied oral forms. Semax is a synthetic peptide studied primarily in Russian neurological research; its nootropic effects in healthy Western populations are essentially uncharacterized in peer-reviewed literature.

What did they get wrong (or right)?

The sequencing logic is reasonable. Starting with a GLP-1, stabilizing, then layering is a more measured approach than dumping five compounds in at once. That part she got right, and it reflects what most clinicians who work with peptides actually recommend.

What she got wrong, or at least oversimplified, is framing each peptide as reliably producing a specific outcome. "Skin laxity looks better" after GHK-Cu is plausible but unverifiable without controls. Attributing cognitive improvement specifically to Semax over everything else she's taking simultaneously is not scientifically credible, despite her own "one at a time" advice. She also conflates perimenopause as justification for a multi-peptide stack in a way that implies these compounds address hormonal changes, which is not established. None of these peptides are approved or clinically validated for perimenopause symptom management. The casual stacking of growth hormone secretagogues with GLP-1 medications also raises interaction questions she doesn't address.

What should you actually know?

Most of these peptides are not FDA-approved for the uses described. They are used off-label through compounding pharmacies, which means quality, purity, and dosing consistency vary considerably by source.

Growth hormone secretagogues like CJC-1295 and ipamorelin are on the FDA's list of compounds withdrawn from compounding due to safety and efficacy concerns as of 2024, which is a material fact this video does not mention. Anyone considering this stack needs a prescribing clinician who can run baseline labs, monitor IGF-1 levels, and assess whether GH elevation is appropriate for them specifically. Women in perimenopause already have shifting hormone profiles; adding growth hormone axis stimulation without medical oversight is not a low-risk experiment. Semax is not commercially available in the US through regulated channels. NAD infusions, which this likely refers to, have a real but overhyped evidence base. The "start one at a time" principle she closes with is genuinely good advice, but it cannot substitute for clinical evaluation before starting any of these compounds.